<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The Drosophila discs large <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor homologue-3 (MPP3), a putative <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor involved in cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and cell polarity, is frequently inactivated in several <z:mp ids='MP_0002038'>carcinomas</z:mp> due to promoter hypermethylation </plain></SENT>
<SENT sid="1" pm="."><plain>The alteration of MPP3 methylation in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> has not been investigated </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To determine the role of inactivated MPP3 in colorectal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and the potential clinical application as a novel epigenetic marker </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We measured MPP3 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression and promoter methylation in 6 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines, 23 primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> and corresponding non-cancerous tissues </plain></SENT>
<SENT sid="4" pm="."><plain>The correlations between MPP3 expression, DNA methylation and clinicopathological characteristics were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Loss of MPP3 expression was observed in 2 of 6 (33.3%) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines and 10 of 23 (43.5%) primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>MPP3 promoter hypermethylation also occurred in the same <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines (SW1116 and LoVo) and 9 of 23 (39.1%) primary colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Among <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> loss of MPP3 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, the promoter hypermethylation rate was 80%, which was significantly higher than <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with over-expressed MPP3 (7.7%, P=0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>After treated with 5-aza-dC, two cell lines (SW1116 and LoVo) revealed significant restoration of MPP3 expression </plain></SENT>
<SENT sid="9" pm="."><plain>MPP3 promoter methylation was also significantly higher in advanced colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (57.1%) compared with early stage <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> (11.1%) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: These preliminary data suggested that epigenetic inactivation of MPP3 frequently occurred during the development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and might also be a potential biomarker for molecular classification of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>